Latest research highlights the role of surgery in tackling type 2
diabetes
NORDERSTEDT, Germany--(BUSINESS WIRE)--
Ethicon, the medical devices subsidiary of Johnson & Johnson, is
committed to leading the way in resolving the burden of obesity for both
patients and healthcare systems around the world, by expanding access
and demonstrating the critical value of treatment.
As strong supporters of evidenced-based treatment, Ethicon welcomes the
publication of new researchsuggesting that surgery could
play an important role in the treatment of patients suffering with type
2 diabetes. New guidelines1, published in DiabetesCare,
and presented at a podium presentation during the recent Annual American
Diabetes Association (ADA) Scientific Sessions, state that metabolic
surgery should be considered for the treatment of type 2 diabetes in
patients with obesity (BMI > 30 kg/m2 or > 27.5 for patients of Asian
descent) when hyper-glycaemia is inadequately controlled by lifestyle
and optimal medical therapy. The guidelines are endorsed by 45 worldwide
societies (30 medical and 15 surgical organizations) at the time of
publication, including the International Diabetes Federation, American
Diabetes Association and Diabetes UK.
The guidelines are supported by mechanistic and clinical evidence
including 11 randomized clinical trials. In further support for these
conclusions, the final, five year follow up data from the STAMPEDE2
(Surgical Treatment and Medications Potentially Eradicate Diabetes
Efficiently) clinical trial, reinforces the role of surgery for the
treatment of obese patients with type 2 diabetes. The findings, which
were discussed during the European Obesity Summit (EOS) in Gothenburg
this month, show that bariatric surgery's beneficial effects on blood
glucose control in mild and moderately obese patients with type 2
diabetes may persist for up to five years. Furthermore, patients who
received bariatric surgery were more able to control their type 2
diabetes over time compared with intensive medical therapy alone.
Speaking at the symposium, Dr. Francesco Rubino, Professor of surgery
and Chair of Metabolic and Bariatric Surgery, King's College London
commented: "While prevention of diabetes remains crucial, patients with
established disease should have access to effective treatment options;
evidence has now proved that surgery can be the best option for some
people with type 2 diabetes." He continued: "The DSS-II guidelines are a
real game changer because they effectively establish surgery, for the
first time, as a standard diabetes treatment option. This conclusion is
endorsed by 45 worldwide organizations, an unprecedented level of
consensus in the medical community."
The symposium also focused attention on a report3 developed
in collaboration with the Economist Intelligence Unit(EIU),
which studied the current national and EU-level approaches to obesity
policy, identifying weaknesses in current efforts across Europe.
"A more holistic and cost effective strategy is needed to tackle
obesity." said Silvia De Dominicis, Ethicon Franchise VP EMEA. "What's
important now is that the member states of Europe collectively recognize
that those suffering from obesity should be treated as patients. We hope
that this latest research helps to initiate a critical dialogue with
policymakers in order to help shape the future of obesity management.
It's time to act."
Obesity and metabolic disease have reached pandemic proportions, as
nearly 30 percent of the world's population - 2.1 billion people - are
overweight or obese4. As obesity rates have increased, so
have those for type 2 diabetes, and 25-27 percent of the obese
population has type 2 diabetes5. In Europe, it is now
estimated that 20 percent of the adult population is obese,6 and
this has significant economic implications too, with more than €33
billion annual health care costs being attributed to obesity.7
- Ends -
Notes to editor
About Ethicon: From creating the first sutures, to
revolutionizing surgery with minimally invasive procedures, Ethicon* has
made significant contributions to surgery for more than 60 years. Our
continuing dedication to Shape the Future of Surgery is built on
our commitment to help address the world's most pressing healthcare
issues, and improve and save more lives. Through Ethicon's surgical
technologies and solutions including sutures, staplers, energy devices,
trocars and hemostats, and our commitment to treat serious medical
conditions like obesity and cancer worldwide, we deliver innovation to
make a life-changing impact. Learn more at www.ethicon.com,
and follow us on Twitter @Ethicon.
* Ethicon represents the products and services of Johnson & Johnson
Medical Limited, Ethicon Endo-Surgery (Europe) GmbH and certain of their
affiliates.
References:
1. Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for
Type 2 Diabetes: A Joint Statement by International Diabetes
Organizations. Diabetes Care June 2016;39:861-877
2. Bariatric Surgery Still Tops Meds for Glycemic Control at 5 Years:
STAMPEDE. Medscape. Apr 14, 2016
3. Economist Intelligence Unit. 2015. Confronting Obesity in Europe:
Taking action to change the default setting. Available at http://www.eiu.com/industry/article/733713257/white-paper---confronting-obesity-in-europe/2015-11-26
4. Dobbs, R., Sawers, C., Thompson, F., Manyika, J., Woetzel, J., Child,
P., McKenna, S., Spatharou, A. (2014, November 1). How the world could
better fight obesity. Available at http://www.mckinsey.com/insights/economic_studies/how_the_world_could_better_fight_obesity.
5. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to
diabetes mellitus, hypertension and dyslipidaemia: comparison of data
from two national surveys. International Journal of Clinical
Practice,61(5), 737-747. 2007. http://doi.org/10.1111/j.1742-1241.2007.01336.x
6. World Health Organization Health Topics. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics
pulled 5/10/2016
7. Fry J, Finley W. The prevalence and costs of obesity in the EU.
Proceedings of the Nutrition Society. 2005;64:359-362
© 2016 Ethicon Endo-Surgery (Europe) GmbH 054476-160608 EMEA
View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005574/en/
Ethicon Endo-Surgery (Europe) GmbH
Dawn Trail, +49 (0)6209
796 8906
DTrail@its.JNJ.com
or
Publicis
Life Brands Resolute
Julia Kirby, +44 (0) 7966 833136
ethicon@publicislifebrandsresolute.com
Source: Ethicon
News Provided by Acquire Media